Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sota-ES
NCT07498803Phase 2Not yet recruiting
- Sponsor
- Philipps-Universität Marburg
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of sotatercept in Eisenmenger syndrome, congenital heart disease (CHD), pulmonary arterial hypertension (PAH), sponsored by Philipps-Universität Marburg. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sotatercept
03
Conditions
Eisenmenger syndromecongenital heart disease (CHD)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07498803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498803.